去甲肾上腺素剂量与危重症患者死亡率的关联:系统评价与剂量-反应荟萃分析
该系统评价与剂量-反应荟萃分析检索2013年1月1日至2024年10月30日MEDLINE、Embase和Web of Science,纳入19项研究共29,935例危重症成人,其中6项进入荟萃分析。主要结局为死亡率。结果显示去甲肾上腺素峰值剂量每增加0.1 µg/kg/min,相对风险升高约1.5倍,剂量-死亡率曲线未见拐点。按SOFA-2去甲肾上腺素剂量分类,医院死亡率在≤0.2 µg/kg/min组为16.5%,>0.2至0.4 µg/kg/min组为31.9%,>0.4 µg/kg/min组为40.3%(p < 0.001)。作者认为去甲肾上腺素剂量可作为心血管衰竭严重程度的标志物。
要点
- 危重症成人中去甲肾上腺素峰值剂量每增加0.1 µg/kg/min,死亡相对风险升高约1.5倍。
- 剂量-死亡率曲线未见拐点,死亡风险随剂量增加呈指数上升。
- SOFA-2剂量分类:≤0.2 µg/kg/min组医院死亡率16.5%,>0.2至0.4 µg/kg/min组31.9%,>0.4 µg/kg/min组40.3%(p < 0.001)。
- 该系统评价纳入19项研究共29,935例患者,其中6项进入荟萃分析。
- 作者认为去甲肾上腺素剂量可作为心血管衰竭严重程度的标志物。
适用人群与场景
- 危重症成人(系统评价与荟萃分析纳入人群)。
研究设计与关键结果
- 研究类型:系统评价与剂量-反应荟萃分析,检索MEDLINE、Embase和Web of Science(2013年1月1日至2024年10月30日),遵循PRISMA指南,注册于PROSPERO(CRD42024501533)。
- 纳入19项研究共29,935例危重症成人,其中6项进入荟萃分析。
- 主要结局为死亡率;去甲肾上腺素峰值剂量每增加0.1 µg/kg/min,相对风险升高约1.5倍,剂量-死亡率曲线未见拐点。
- 按SOFA-2去甲肾上腺素剂量分类,医院死亡率:≤0.2 µg/kg/min组16.5%,>0.2至0.4 µg/kg/min组31.9%,>0.4 µg/kg/min组40.3%(p < 0.001)。
证据类型、等级与局限
- 证据类型:系统评价与剂量-反应荟萃分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为去甲肾上腺素剂量可作为心血管衰竭严重程度的标志物。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Noradrenaline is currently the first-line vasopressor in treatment of circulatory failure. Its dose reflects illness severity, and together with dopamine, dobutamine and adrenaline, it is used in the Sequential Organ Failure Assessment (SOFA) score to grade cardiovascular dysfunction. Over the years, noradrenaline use has increased and it has largely replaced dopamine. As part of the SOFA-2 update, we conducted a systematic review and dose-response meta-analysis to assess the association between noradrenaline dose and mortality.
METHODS: We searched MEDLINE, Embase, and Web of Science from 1 January 2013 to 30 October 2024 for studies reporting mortality by noradrenaline dose in critically ill adults. The primary outcome was mortality. We generated pooled relative risks (RR) and assessed linear and non-linear dose-response relationships. Mortality was also analysed by SOFA-2 noradrenaline categories. The study followed PRISMA guidelines and was registered with PROSPERO (CRD42024501533).
RESULTS: Nineteen studies, including totally 29,935 patients, were included in the systematic review, and six in the meta-analysis. We observed a consistent increase in mortality: the relative risk escalated by a factor of 1.5 for every 0.1 µg/kg/min increase in peak noradrenaline dose. We did not find inflection points in the dose-mortality curve. In SOFA-2 categories, hospital mortality was 16.5% in the dose category ≤ 0.2 µg/kg/min, 31.9% in the category > 0.2 to 0.4 µg/kg/min, and 40.3% in the category > 0.4 µg/kg/min (p < 0.001).
CONCLUSIONS: In critically ill patients, escalating doses of noradrenaline correlate with an exponentially rising relative risk of mortality. This dose-dependent pattern reinforces the role of noradrenaline dose as a marker of cardiovascular failure severity.
参考来源
- Reinikainen M, Delamarre L, Blaser AR, et al. Association of noradrenaline dose with mortality in critically ill patients: a systematic review and dose-response meta-analysis. Crit Care. 2025. PMID: 41267052. doi:10.1186/s13054-025-05717-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。